Corsera Health Secures $80M Series A Funding Led by Forbion and Population Health Partners

Why It Matters

The infusion of $80 million accelerates development of once‑annual RNAi therapeutics that could transform cardiovascular prevention, while the AI‑driven Klotho platform promises population‑scale risk stratification and cost‑effective treatment pathways.

Key Takeaways

• $80M Series A led by Forbion, Population Health Partners.
• Funds target RNAi medicines for LDL-C and blood pressure.
• COR-1004 Phase 1 starts, proof of concept 2026.
• AI platform Klotho predicts cardiovascular risk and treatment benefit.
• Board adds Forbion GP Marco Boorsma.

Pulse Analysis

Cardiovascular disease remains the leading cause of mortality worldwide, driving a relentless demand for innovative prevention strategies. Traditional lipid‑lowering drugs and antihypertensives have saved countless lives, yet adherence challenges and the need for lifelong dosing limit their impact. RNAi offers a paradigm shift by silencing disease‑causing genes with a single, subcutaneous injection that can last a year or longer. Corsera Health’s dual‑target program—silencing PCSK9 to reduce LDL‑C and AGT to lower blood pressure—aims to deliver exactly that breakthrough, positioning the company at the forefront of next‑generation cardiovascular therapeutics.

The $80 million Series A round, led by biotech investor Forbion and population‑health specialist Population Health Partners, provides Corsera with the runway to scale both its drug pipeline and its AI‑enabled Klotho platform. Klotho leverages machine‑learning models to estimate an individual’s lifetime cardiovascular risk and quantify the health‑span gains from LDL‑C and blood‑pressure reductions, creating a data‑driven justification for preventive treatment. The financing also brings seasoned biotech leader John Maraganore onto the cap table and adds Forbion General Partner Marco Boorsma to the board, bolstering strategic guidance and industry connections.

Corsera has already initiated a Phase 1 study of COR‑1004, its siRNA targeting PCSK9, with safety, tolerability and LDL‑C knock‑down as primary readouts. Proof‑of‑concept data are expected by the end of 2026, after which the company plans to advance COR‑2003, the AGT‑targeting candidate, into its own Phase 1 trial. If successful, annual dosing could dramatically lower treatment costs and improve adherence, opening a sizable market that spans primary prevention and high‑risk patients. The combination of gene‑silencing therapeutics and predictive AI analytics positions Corsera to attract further capital and partnership opportunities in the rapidly evolving cardiovascular space.

Deal Summary

Corsera Health, a Boston‑based clinical‑stage cardiovascular health company, announced an $80 million Series A round led by Forbion and Population Health Partners, with participation from co‑founder John Maraganore. The funding will support the development of its RNAi‑based preventive medicines and its AI‑enabled precision‑health platform Klotho. The round was disclosed on January 7, 2026.